Quick Answer
AIM ImmunoTech Inc. reported Total Revenue of $88.0 thousand for fiscal year 2025.
AIM ImmunoTech Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $88.0K -48.2% |
$170.0K -15.8% |
$202.0K +43.3% |
$141.0K +4.4% |
$135.0K -17.2% |
$163.0K +16.4% |
| Revenue (ASC 606) | $88.0K -48.2% |
$170.0K -15.8% |
$202.0K +43.3% |
$141.0K +4.4% |
$135.0K -17.2% |
$163.0K +16.4% |
| Net Income | -$13.96M +19.4% |
-$17.32M +40.2% |
-$28.96M -48.9% |
-$19.45M -1.7% |
-$19.13M -32.8% |
-$14.40M -53.1% |
| Diluted EPS | -$8.62 +72.1% |
-$30.92 -5053.3% |
-$0.60 -50.0% |
-$0.40 | — | — |
| Total Assets | $5.78M -32.8% |
$8.61M -55.6% |
$19.38M -52.1% |
$40.49M -29.8% |
$57.70M -10.7% |
$64.58M +211.2% |
| Cash and Equivalents | $2.98M +75.5% |
$1.70M -68.7% |
$5.44M -79.9% |
$27.05M -15.7% |
$32.09M -16.6% |
$38.50M +2519.1% |
| Long-Term Debt | — | — | — | — | — | $1.88M -10.8% |
| Stockholders Equity | -$9.78M -640.0% |
-$1.32M -112.9% |
$10.23M -73.4% |
$38.47M -32.4% |
$56.88M -7.2% |
$61.29M +356.0% |
| R&D Expense | $3.92M -36.7% |
$6.20M -43.3% |
$10.94M +56.5% |
$6.99M -8.9% |
$7.67M +34.1% |
$5.72M +23.0% |
| Operating Income | -$11.66M +41.0% |
-$19.77M +38.0% |
-$31.92M -60.2% |
-$19.92M -5.8% |
-$18.84M -24.3% |
-$15.15M -21.8% |
| Shares Outstanding | 3.07M +368.5% |
655,262 -98.7% |
49.10M +2.1% |
48.08M +0.2% |
47.99M +13.9% |
42.15M +305.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $26.0K | -25.7% | +4.0% |
| Revenue (ASC 606) | September 30, 2025 | $26.0K | -25.7% | +4.0% |
| Net Income | September 30, 2025 | -$3.28M | +11.2% | -17.5% |
| Diluted EPS | September 30, 2025 | $1.57 | +126.2% | +142.7% |
| Total Assets | September 30, 2025 | $5.49M | -59.6% | +33.1% |
| Cash and Equivalents | September 30, 2025 | $2.35M | +156.5% | +393.1% |
| Long-Term Debt | March 31, 2021 | $1.82M | -11.4% | -3.2% |
| Stockholders Equity | September 30, 2025 | -$6.08M | -308.7% | +7.2% |
| R&D Expense | September 30, 2025 | $607.0K | -57.8% | -48.3% |
| Operating Income | September 30, 2025 | -$2.45M | +45.5% | +7.5% |
| Shares Outstanding | September 30, 2025 | 2.76M | -95.3% | +261.7% |
- AIM ImmunoTech Inc. reported Total Revenue of $88.0 thousand for fiscal year 2025.
- AIM ImmunoTech Inc. showed a decrease of -48.2% in Total Revenue compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported Revenue (ASC 606) of $88.0 thousand for fiscal year 2025.
- AIM ImmunoTech Inc. showed a decrease of -48.2% in Revenue (ASC 606) compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported Net Income of -$13.96 million for fiscal year 2025.
- AIM ImmunoTech Inc. showed an increase of +19.4% in Net Income compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported Diluted EPS of $8.62 per share (loss) for fiscal year 2025.
- AIM ImmunoTech Inc. showed an increase of +72.1% in Diluted EPS compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported Total Assets of $5.78 million for fiscal year 2025.
- AIM ImmunoTech Inc. showed a decrease of -32.8% in Total Assets compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported Cash and Equivalents of $2.98 million for fiscal year 2025.
- AIM ImmunoTech Inc. showed an increase of +75.5% in Cash and Equivalents compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported Long-Term Debt of $1.88 million for fiscal year 2020.
- AIM ImmunoTech Inc. showed a decrease of -10.8% in Long-Term Debt compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported Stockholders Equity of -$9.78 million for fiscal year 2025.
- AIM ImmunoTech Inc. showed a decrease of -640.0% in Stockholders Equity compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported R&D Expense of $3.92 million for fiscal year 2025.
- AIM ImmunoTech Inc. showed a decrease of -36.7% in R&D Expense compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported Operating Income of -$11.66 million for fiscal year 2025.
- AIM ImmunoTech Inc. showed an increase of +41.0% in Operating Income compared to the prior fiscal year.
- AIM ImmunoTech Inc. reported Shares Outstanding of 3.07 million shares for fiscal year 2025.
- AIM ImmunoTech Inc. showed an increase of +368.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: